董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Miles Davies | 男 | Director | 42 | 7.70万美元 | 未持股 | 2023-10-18 |
| Alan Fisher | 男 | Chairman of the Board | 70 | 8.70万美元 | 未持股 | 2023-10-18 |
| Jane Ryan | 女 | Director | 64 | 9.31万美元 | 未持股 | 2023-10-18 |
| Aaron Weaver | 男 | Director | 42 | 7.70万美元 | 未持股 | 2023-10-18 |
| David Wilson | 男 | Director | 60 | 8.70万美元 | 未持股 | 2023-10-18 |
| Errol De Souza | 男 | Director | 68 | 402.72万美元 | 未持股 | 2023-10-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Liz Doolin | 女 | Vice President Clinical Development | 58 | 29.04万美元 | 未持股 | 2023-10-18 |
| Spyros Papapetropoulos | 男 | President and Chief Executive Officer | 51 | 未披露 | 未持股 | 2023-10-18 |
| Tim Cunningham | 男 | Chief Financial Officer | 61 | 未披露 | 未持股 | 2023-10-18 |
董事简历
中英对照 | 中文 | 英文- Miles Davies
-
Miles Davies自2021年7月起担任我们的董事会成员。Davies先生自2021年2月起担任Apeiron Investment Group Ltd.的医疗保健总经理。在此之前，Davies先生于2006年至2021年2月担任Rothschild&Co.的董事。Davies先生在苏格兰爱丁堡大学获得硕士学位。
Miles Davies,has served as a member of Bionomics Limited board of directors since July 2021. Mr. Davies has worked at Apeiron Investment Group Ltd in the Healthcare team since February 2021. Prior to that, Mr. Davies was at Rothschild & Co. from 2006 to February 2021. Mr. Davies received his Master's Degree from The University of Edinburgh, Scotland. - Miles Davies自2021年7月起担任我们的董事会成员。Davies先生自2021年2月起担任Apeiron Investment Group Ltd.的医疗保健总经理。在此之前，Davies先生于2006年至2021年2月担任Rothschild&Co.的董事。Davies先生在苏格兰爱丁堡大学获得硕士学位。
- Miles Davies,has served as a member of Bionomics Limited board of directors since July 2021. Mr. Davies has worked at Apeiron Investment Group Ltd in the Healthcare team since February 2021. Prior to that, Mr. Davies was at Rothschild & Co. from 2006 to February 2021. Mr. Davies received his Master's Degree from The University of Edinburgh, Scotland.
- Alan Fisher
-
Alan Fisher自2016年8月起担任我们的董事会成员。他也是审计和风险管理委员会主席，提名和薪酬委员会成员。他曾一直担任Fisher Corporate Advisory Pty Ltd.的董事总经理（1997年以来），在那里他曾建议公共和私人公司的并购、公共和私人股本融资、业务重组和战略建议。他目前在多家澳交所上市公司的董事会任职，包括CentrePoint，Alliance Limited主席，自2015年以来是一家金融许可，资金管理和咨询服务提供商，IDT Australia Limited（主席），一家制药产品的开发商和制造商，自2015年以来；投资公司Thorney Technologies Limited（非执行董事-审计和风险管理委员会主席）自2016年以来；医疗技术公司Simavita Limited自2019年以来专注于平台技术的开发。从1974年到1997年，Fisher先生担任Coopers&Lybrand的公司财务合伙人。Fisher先生获得了澳大利亚墨尔本大学的会计学士学位，并且是澳大利亚和新西兰特许会计师协会的会员。
Alan Fisher,previously a non-executive member of the Board since September 1, 2016 and Chair of the Audit & Risk Committee, was appointed Non-Executive Chair of the Board, effective from July 1, 2023. He is also Chair of the Audit and Risk Management Committee and a member of the Nomination and Remuneration Committee. Mr. Fisher has served as the Managing Director of Fisher Corporate Advisory Pty Ltd. since 1997, where he advises public and private companies on mergers and acquisitions, public and private equity raisings, business restructuring and strategic advice. He currently serves on the board of several ASX-listed companies, including Centrepoint, Alliance Limited (Chair), a financial licensee, funds management and advice services provider since 2015; IDT Australia Limited (Chair), a developer and manufacturer of pharmaceutical products, since 2015; Thorney Technologies Limited (Non-Executive Director – Chair of Audit and Risk Management Committee), an investment company, since 2016; and Simavita Limited, a medical technology company focused on the development of platform technologies, since 2019. Mr. Fisher served as a Corporate Finance Partner of Coopers & Lybrand from 1974 to 1997. Mr. Fisher received his B.Com., Accounting from the University of Melbourne, Australia and is a Fellow of the Australian and New Zealand Institute of Chartered Accountants. - Alan Fisher自2016年8月起担任我们的董事会成员。他也是审计和风险管理委员会主席，提名和薪酬委员会成员。他曾一直担任Fisher Corporate Advisory Pty Ltd.的董事总经理（1997年以来），在那里他曾建议公共和私人公司的并购、公共和私人股本融资、业务重组和战略建议。他目前在多家澳交所上市公司的董事会任职，包括CentrePoint，Alliance Limited主席，自2015年以来是一家金融许可，资金管理和咨询服务提供商，IDT Australia Limited（主席），一家制药产品的开发商和制造商，自2015年以来；投资公司Thorney Technologies Limited（非执行董事-审计和风险管理委员会主席）自2016年以来；医疗技术公司Simavita Limited自2019年以来专注于平台技术的开发。从1974年到1997年，Fisher先生担任Coopers&Lybrand的公司财务合伙人。Fisher先生获得了澳大利亚墨尔本大学的会计学士学位，并且是澳大利亚和新西兰特许会计师协会的会员。
- Alan Fisher,previously a non-executive member of the Board since September 1, 2016 and Chair of the Audit & Risk Committee, was appointed Non-Executive Chair of the Board, effective from July 1, 2023. He is also Chair of the Audit and Risk Management Committee and a member of the Nomination and Remuneration Committee. Mr. Fisher has served as the Managing Director of Fisher Corporate Advisory Pty Ltd. since 1997, where he advises public and private companies on mergers and acquisitions, public and private equity raisings, business restructuring and strategic advice. He currently serves on the board of several ASX-listed companies, including Centrepoint, Alliance Limited (Chair), a financial licensee, funds management and advice services provider since 2015; IDT Australia Limited (Chair), a developer and manufacturer of pharmaceutical products, since 2015; Thorney Technologies Limited (Non-Executive Director – Chair of Audit and Risk Management Committee), an investment company, since 2016; and Simavita Limited, a medical technology company focused on the development of platform technologies, since 2019. Mr. Fisher served as a Corporate Finance Partner of Coopers & Lybrand from 1974 to 1997. Mr. Fisher received his B.Com., Accounting from the University of Melbourne, Australia and is a Fellow of the Australian and New Zealand Institute of Chartered Accountants.
- Jane Ryan
-
Jane Ryan自2020年10月以来一直担任我们的董事会成员。Ryan博士是审计和风险管理委员会的成员以及提名和薪酬委员会的成员。自2014年1月起，Ryan博士为生物技术公司提供执行级别的咨询服务，涉及资本筹集、业务开发和并购。自2021年3月以来，她一直担任BCAL Diagnostics的商业和产品开发顾问，BCAL Diagnostics是一家在ASX上市的癌症诊断公司。从2014年到2017年，Ryan博士担任Sementis Ltd.（一家未上市的开发疫苗技术的上市公司）的首席执行官。此前，她曾担任Biota Holdings公司（澳交所上市的生物技术公司）的产品开发的执行官兼部门领导，在那里她曾负责监督Biota Holdings公司的开发投资组合和项目。自2018年8月以来，Ryan博士一直担任澳大利亚证券交易所上市公司Anatara Lifesciences的董事，她也是澳大利亚董事协会的成员。她获得了学士学位。她在澳大利亚国立大学获得博士学位，在麦考瑞大学获得博士学位，并在哥伦比亚大学担任博士后研究员。
Jane Ryan,has served as a member of Bionomics Limited board of directors since October 2020. Dr. Ryan is a member of the Audit and Risk Management Committee and a member of the Nomination and Remuneration Committee. Since January 2014, Dr. Ryan has provided executive level advisory services to biotechnology companies in connection with capital raising, business development, and mergers and acquisitions. In this capacity, she has served as a commercial and product development advisor to BCAL Diagnostics, a cancer diagnostics company listed on the ASX, since March 2021. From 2014 to 2017, Dr. Ryan served as the CEO of Sementis Ltd., a public company (unlisted) developing vaccine technology. Prior to that, Dr. Ryan was an executive and division leader of product development at Biota Holdings, a biotechnology company which was listed on the ASX, where she provided oversight to Biota Holdings' development portfolio and programs. Dr. Ryan has served as a director of Anatara Lifesciences since August 2018 and IDT Australia Limited since January 2022, both listed companies. She is also a member of the Australian Institute of Company Directors. She received her B.Sc. from the Australia National University, her Ph.D. from Macquarie University and was a Postdoctoral Fellow at Columbia University. - Jane Ryan自2020年10月以来一直担任我们的董事会成员。Ryan博士是审计和风险管理委员会的成员以及提名和薪酬委员会的成员。自2014年1月起，Ryan博士为生物技术公司提供执行级别的咨询服务，涉及资本筹集、业务开发和并购。自2021年3月以来，她一直担任BCAL Diagnostics的商业和产品开发顾问，BCAL Diagnostics是一家在ASX上市的癌症诊断公司。从2014年到2017年，Ryan博士担任Sementis Ltd.（一家未上市的开发疫苗技术的上市公司）的首席执行官。此前，她曾担任Biota Holdings公司（澳交所上市的生物技术公司）的产品开发的执行官兼部门领导，在那里她曾负责监督Biota Holdings公司的开发投资组合和项目。自2018年8月以来，Ryan博士一直担任澳大利亚证券交易所上市公司Anatara Lifesciences的董事，她也是澳大利亚董事协会的成员。她获得了学士学位。她在澳大利亚国立大学获得博士学位，在麦考瑞大学获得博士学位，并在哥伦比亚大学担任博士后研究员。
- Jane Ryan,has served as a member of Bionomics Limited board of directors since October 2020. Dr. Ryan is a member of the Audit and Risk Management Committee and a member of the Nomination and Remuneration Committee. Since January 2014, Dr. Ryan has provided executive level advisory services to biotechnology companies in connection with capital raising, business development, and mergers and acquisitions. In this capacity, she has served as a commercial and product development advisor to BCAL Diagnostics, a cancer diagnostics company listed on the ASX, since March 2021. From 2014 to 2017, Dr. Ryan served as the CEO of Sementis Ltd., a public company (unlisted) developing vaccine technology. Prior to that, Dr. Ryan was an executive and division leader of product development at Biota Holdings, a biotechnology company which was listed on the ASX, where she provided oversight to Biota Holdings' development portfolio and programs. Dr. Ryan has served as a director of Anatara Lifesciences since August 2018 and IDT Australia Limited since January 2022, both listed companies. She is also a member of the Australian Institute of Company Directors. She received her B.Sc. from the Australia National University, her Ph.D. from Macquarie University and was a Postdoctoral Fellow at Columbia University.
- Aaron Weaver
-
Aaron Weaver自2020年7月以来一直担任我们的董事会成员。Weaver先生分别自2021年6月和2019年5月起担任Apeiron Investments的负责人和资本市场主管，他专注于生命科学领域。在此之前，他于2019年5月至2021年6月担任Atai Life Sciences AG的高级总法律顾问兼投资者关系主管，该公司是一家临床阶段的生物制药公司，专注于开发治疗情绪障碍，成瘾和焦虑的疗法。他是英国的特许金融分析师和注册律师。2013年6月至2017年8月，他是伦敦瑞士信贷资本市场解决方案团队的投资银行家。2007年6月至2013年6月，他是伦敦Allen&Overy LLP的资本市场律师。Weaver先生在昆士兰科技大学获得法学硕士学位，并在昆士兰大学获得工商管理学士学位和法学学士学位。
Aaron Weaver,has served as a member of Bionomics Limited board of directors since July 2020. Mr. Weaver served as a Principal and Head of Capital Markets at Apeiron Investments since June 2021 and May 2019, respectively, where he has focused on the life sciences sector. Prior to that, he served as Senior General Counsel and Lead, Investor Relations, at atai Life Sciences AG, a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of mood disorders, addiction and anxiety, from May 2019 to June 2021. He is a Chartered Financial Analyst and a registered solicitor in the United Kingdom. From June 2013 to August 2017, he was an investment banker at Credit Suisse in London within the Capital Markets Solutions team. He was a capital markets solicitor at Allen & Overy LLP, London from June 2007 to June 2013. Mr. Weaver received his Masters of Law from the Queensland University of Technology and a Bachelor's of Business Administration and Bachelors of Laws from the University of Queensland. - Aaron Weaver自2020年7月以来一直担任我们的董事会成员。Weaver先生分别自2021年6月和2019年5月起担任Apeiron Investments的负责人和资本市场主管，他专注于生命科学领域。在此之前，他于2019年5月至2021年6月担任Atai Life Sciences AG的高级总法律顾问兼投资者关系主管，该公司是一家临床阶段的生物制药公司，专注于开发治疗情绪障碍，成瘾和焦虑的疗法。他是英国的特许金融分析师和注册律师。2013年6月至2017年8月，他是伦敦瑞士信贷资本市场解决方案团队的投资银行家。2007年6月至2013年6月，他是伦敦Allen&Overy LLP的资本市场律师。Weaver先生在昆士兰科技大学获得法学硕士学位，并在昆士兰大学获得工商管理学士学位和法学学士学位。
- Aaron Weaver,has served as a member of Bionomics Limited board of directors since July 2020. Mr. Weaver served as a Principal and Head of Capital Markets at Apeiron Investments since June 2021 and May 2019, respectively, where he has focused on the life sciences sector. Prior to that, he served as Senior General Counsel and Lead, Investor Relations, at atai Life Sciences AG, a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of mood disorders, addiction and anxiety, from May 2019 to June 2021. He is a Chartered Financial Analyst and a registered solicitor in the United Kingdom. From June 2013 to August 2017, he was an investment banker at Credit Suisse in London within the Capital Markets Solutions team. He was a capital markets solicitor at Allen & Overy LLP, London from June 2007 to June 2013. Mr. Weaver received his Masters of Law from the Queensland University of Technology and a Bachelor's of Business Administration and Bachelors of Laws from the University of Queensland.
- David Wilson
-
David Wilson自2016年6月起担任公司董事会成员。他也是提名和薪酬委员会的主席，以及审计和风险管理委员会的成员。2011年11月以来，他担任WG Partners LLP的主席兼首席执行官，这是一家投资银行精品公司，为生命科学公司的企业融资、并购和融资提供建议。在加入WG Partners LLP之前，Wilson先生从2001年到2011年在Piper Jeffrey担任各种职务，包括欧洲业务首席执行官，全球医疗保健团队主席和全球运营委员会成员。他也曾担任ING Investment Banking公司的董事总经理（从1999年到2001年），以及Deutsche Bank公司的小公司企业融资主管（从1998年到1999年）。自2021年7月以来，他目前是几家私人控股公司的董事会成员，包括CS Pharmaceuticals Limited（一家位于英国的制药公司）。Wilson先生在剑桥大学获得学士学位。
David Wilson,has served as a member of Bionomics Limited board of directors since June 2016. He is also Chair of the Nomination and Remuneration Committee and a member of the Audit and Risk Management Committee. He has served as the Chairman and CEO of WG Partners LLP, an investment banking boutique advising life sciences companies on corporate finance, mergers and acquisitions, and capital raising, since November 2011. Prior to WG Partners LLP, Mr. Wilson worked at Piper Jeffrey in various roles from 2001 to 2011, including CEO of European Operations, Chairman of the Global Healthcare Team and a Member of the Global Operating Board. He was also a Managing Director of ING Investment Banking from 1999 to 2001 and the Head of Small Companies Corporate Finance at Deutsche Bank from 1998 to 1999. He is currently on the board of directors of several privately held companies, including CS Pharmaceuticals Limited, a pharmaceutical company based in the United Kingdom, since July 2021. Mr. Wilson received his Bachelor's degree from the University of Cambridge. - David Wilson自2016年6月起担任公司董事会成员。他也是提名和薪酬委员会的主席，以及审计和风险管理委员会的成员。2011年11月以来，他担任WG Partners LLP的主席兼首席执行官，这是一家投资银行精品公司，为生命科学公司的企业融资、并购和融资提供建议。在加入WG Partners LLP之前，Wilson先生从2001年到2011年在Piper Jeffrey担任各种职务，包括欧洲业务首席执行官，全球医疗保健团队主席和全球运营委员会成员。他也曾担任ING Investment Banking公司的董事总经理（从1999年到2001年），以及Deutsche Bank公司的小公司企业融资主管（从1998年到1999年）。自2021年7月以来，他目前是几家私人控股公司的董事会成员，包括CS Pharmaceuticals Limited（一家位于英国的制药公司）。Wilson先生在剑桥大学获得学士学位。
- David Wilson,has served as a member of Bionomics Limited board of directors since June 2016. He is also Chair of the Nomination and Remuneration Committee and a member of the Audit and Risk Management Committee. He has served as the Chairman and CEO of WG Partners LLP, an investment banking boutique advising life sciences companies on corporate finance, mergers and acquisitions, and capital raising, since November 2011. Prior to WG Partners LLP, Mr. Wilson worked at Piper Jeffrey in various roles from 2001 to 2011, including CEO of European Operations, Chairman of the Global Healthcare Team and a Member of the Global Operating Board. He was also a Managing Director of ING Investment Banking from 1999 to 2001 and the Head of Small Companies Corporate Finance at Deutsche Bank from 1998 to 1999. He is currently on the board of directors of several privately held companies, including CS Pharmaceuticals Limited, a pharmaceutical company based in the United Kingdom, since July 2021. Mr. Wilson received his Bachelor's degree from the University of Cambridge.
- Errol De Souza
-
Errol De Souza，2003年4月起，担任董事。他有着近20年的药物研发经验。他从2010年3月起，担任Biodel的总裁、首席执行官，这是一家专业生物制药上市公司。2003年4月至2009年1月，他担任Archemix Corporation的总裁、首席执行官，这是专注于适体治疗的生物制药公司。2002年9月至2003年3月，他担任Synaptic Pharmaceuticals的总裁、首席执行官、董事。2003年3月的合并业务之后，Synaptic Pharmaceuticals成为国际化制药公司H. Lundbeck A/S的全资子公司。此前，他在Aventis及其前身Hoechst Marion Roussel Pharmaceuticals担任过多个高级管理职务；还曾是Neurocrine Biosciences的共同创始人。他目前是Biodel、Targacept（生命科学上市公司）、Bionomics Limited（澳大利亚生命科学公司，在澳大利亚证券交易所上市）的董事。他在University of Toronto获得生理学士学位（荣誉）、神经内分泌学博士学位，并在The Johns Hopkins University School of Medicine获得神经科学博士后研究员资格。
Errol De Souza,has served as a member of Bionomics Limited board of directors since February 2008, and as Bionomics Limited Chairman from November 2016 and as Bionomics Limited Executive Chairman from November 2018 until July 1, 2023, at which time he transitioned to becoming a non-executive Director. From January 2017 to December 2019, Dr. De Souza served as the President and CEO of Neuropore Therapies, a private biopharmaceutical company focused on the discovery and development of novel small therapeutics for the treatment of neurodegenerative diseases. Prior to that, from March 2010 to January 2016, Dr. De Souza served as the President and CEO of Biodel Inc., a biopharmaceutical company traded on Nasdaq that focused on treatments for endocrine disorders. From March 2009 until March 2010, Dr. De Souza was a pharmaceutical and biotechnology consultant. From April 2003 to March 2009, Dr. De Souza was President and CEO of Archemix Corporation, a private biopharmaceutical company. From September 2002 to March 2003, Dr. De Souza was President and CEO of Synaptic Pharmaceuticals, a biopharmaceutical company traded on Nasdaq which was sold to Lundbeck Pharmaceuticals. Over Dr. De Souza's career, he has served in a number of high-ranking R&D roles, including Senior Vice President and U.S. Head of R&D for Aventis from 1998 to 2002, co-founder and EVP of R&D at Neurocrine from 1992 to 1998 and Head of CNS at DuPont Merck from 1990 to 1992. Dr. De Souza currently serves on the board of several publicly-traded companies, including Catalyst Biosciences, a biopharmaceutical company, since August 2014; Cyclerion Therapeutics, a biopharmaceutical company, since April 2021; and Royalty Pharma, a company that acquires pharmaceutical royalties across the life sciences industry, since October 2008. He has also previously served on the board of directors of IDEXX Laboratories, Inc., a publicly-traded diagnostic company and Palatin Technologies and Neurocrine Biosciences, two publicly-traded biopharmaceutical companies. Dr. De Souza received his Bachelor's degree in physiology and his Ph.D. in neuroendocrinology from the University of Toronto, Canada and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine. - Errol De Souza，2003年4月起，担任董事。他有着近20年的药物研发经验。他从2010年3月起，担任Biodel的总裁、首席执行官，这是一家专业生物制药上市公司。2003年4月至2009年1月，他担任Archemix Corporation的总裁、首席执行官，这是专注于适体治疗的生物制药公司。2002年9月至2003年3月，他担任Synaptic Pharmaceuticals的总裁、首席执行官、董事。2003年3月的合并业务之后，Synaptic Pharmaceuticals成为国际化制药公司H. Lundbeck A/S的全资子公司。此前，他在Aventis及其前身Hoechst Marion Roussel Pharmaceuticals担任过多个高级管理职务；还曾是Neurocrine Biosciences的共同创始人。他目前是Biodel、Targacept（生命科学上市公司）、Bionomics Limited（澳大利亚生命科学公司，在澳大利亚证券交易所上市）的董事。他在University of Toronto获得生理学士学位（荣誉）、神经内分泌学博士学位，并在The Johns Hopkins University School of Medicine获得神经科学博士后研究员资格。
- Errol De Souza,has served as a member of Bionomics Limited board of directors since February 2008, and as Bionomics Limited Chairman from November 2016 and as Bionomics Limited Executive Chairman from November 2018 until July 1, 2023, at which time he transitioned to becoming a non-executive Director. From January 2017 to December 2019, Dr. De Souza served as the President and CEO of Neuropore Therapies, a private biopharmaceutical company focused on the discovery and development of novel small therapeutics for the treatment of neurodegenerative diseases. Prior to that, from March 2010 to January 2016, Dr. De Souza served as the President and CEO of Biodel Inc., a biopharmaceutical company traded on Nasdaq that focused on treatments for endocrine disorders. From March 2009 until March 2010, Dr. De Souza was a pharmaceutical and biotechnology consultant. From April 2003 to March 2009, Dr. De Souza was President and CEO of Archemix Corporation, a private biopharmaceutical company. From September 2002 to March 2003, Dr. De Souza was President and CEO of Synaptic Pharmaceuticals, a biopharmaceutical company traded on Nasdaq which was sold to Lundbeck Pharmaceuticals. Over Dr. De Souza's career, he has served in a number of high-ranking R&D roles, including Senior Vice President and U.S. Head of R&D for Aventis from 1998 to 2002, co-founder and EVP of R&D at Neurocrine from 1992 to 1998 and Head of CNS at DuPont Merck from 1990 to 1992. Dr. De Souza currently serves on the board of several publicly-traded companies, including Catalyst Biosciences, a biopharmaceutical company, since August 2014; Cyclerion Therapeutics, a biopharmaceutical company, since April 2021; and Royalty Pharma, a company that acquires pharmaceutical royalties across the life sciences industry, since October 2008. He has also previously served on the board of directors of IDEXX Laboratories, Inc., a publicly-traded diagnostic company and Palatin Technologies and Neurocrine Biosciences, two publicly-traded biopharmaceutical companies. Dr. De Souza received his Bachelor's degree in physiology and his Ph.D. in neuroendocrinology from the University of Toronto, Canada and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.
高管简历
中英对照 | 中文 | 英文- Liz Doolin
Liz Doolin自2008年以来一直在Bionomics Limited任职，自2018年以来一直担任我们的临床开发副总裁。在加入Bionomics之前，Doolin女士担任New World Bio Limited的药物开发项目经理，这是一家澳大利亚私人生物技术公司，开发基于脂质的疗法。Doolin女士之前是新西兰的一名研究科学家，专门从事免疫学和蛋白质生物技术，以及英国一家生物制药公司的生物过程开发科学家。杜林女士获得了学士学位。和硕士学位。来自新西兰怀卡托大学。
Liz Doolin,has served at Bionomics Limited since 2008 and as Bionomics Limited Vice President of Clinical Development since 2018. Prior to joining Bionomics, Ms. Doolin served as the Project Manager of Drug Development at New World Bio Limited, an Australian private biotechnology company developing lipid-based therapeutics. Ms. Doolin was previously a research scientist in New Zealand specializing in immunology and protein biotechnology, and a bioprocess development scientist for a biopharmaceutical company in the United Kingdom. Ms. Doolin received her B.Sc. and M.Sc. from the University of Waikato, New Zealand.- Liz Doolin自2008年以来一直在Bionomics Limited任职，自2018年以来一直担任我们的临床开发副总裁。在加入Bionomics之前，Doolin女士担任New World Bio Limited的药物开发项目经理，这是一家澳大利亚私人生物技术公司，开发基于脂质的疗法。Doolin女士之前是新西兰的一名研究科学家，专门从事免疫学和蛋白质生物技术，以及英国一家生物制药公司的生物过程开发科学家。杜林女士获得了学士学位。和硕士学位。来自新西兰怀卡托大学。
- Liz Doolin,has served at Bionomics Limited since 2008 and as Bionomics Limited Vice President of Clinical Development since 2018. Prior to joining Bionomics, Ms. Doolin served as the Project Manager of Drug Development at New World Bio Limited, an Australian private biotechnology company developing lipid-based therapeutics. Ms. Doolin was previously a research scientist in New Zealand specializing in immunology and protein biotechnology, and a bioprocess development scientist for a biopharmaceutical company in the United Kingdom. Ms. Doolin received her B.Sc. and M.Sc. from the University of Waikato, New Zealand.
- Spyros Papapetropoulos
Spyros Papapetropoulos自2020年9月起担任我们的首席医疗官。Papapetropoulos博士目前还担任Adamas Pharmaceuticals, Inc.的董事会成员。Nasdaq:ADMS，麻省总医院神经病学顾问。他是Enephalos Life Sciences LLC（神经科学咨询公司）的Founder兼总裁。在加入Vigil之前，Papapetropoulos博士于2019年11月至2020年9月担任Acadia Pharmaceuticals Inc.（纳斯达克市场代码:ACAD）的首席开发官兼高级副总裁，SwanBio Therapeutics的首席执行官，Inc.于2019年4月至2019年9月担任Cavion，Inc.（由Jazz Pharmaceuticals plc（纳斯达克代码:JAZZ）收购）的研发主管兼首席医疗官。在加入Cavion之前，Papapetropoulos博士在多家公司担任管理职位，包括梯瓦制药工业有限公司（纽约证券交易所代码:TEVA）（从2015年2月到2017年6月），辉瑞公司（纽约证券交易所代码:PFE）（从2012年3月到2015年2月），Allergan plc（纽约证券交易所代码:AGN）（从2010年5月到2012年3月）和Biogen Inc.（纳斯达克代码:BIIB）（从2008年4月到2010年5月）。2008年11月至2017年8月，Papapetropoulos博士是迈阿密大学米勒医学院的研究教授，随后担任神经病学志愿教授。Papapetropoulos博士获得了Patras大学健康科学学院的医学博士和博士学位。
Spyros Papapetropoulos has served as our Chief Medical Officer since September 2020. Dr. Papapetropoulos also currently serves as a member of the board of directors of Adamas Pharmaceuticals, Inc. NASDAQ: ADMS and as a consultant in neurology at Massachusetts General Hospital. He is the founder and President of Encephalos Life Sciences LLC, a neurosciences consulting company. Prior to joining Vigil, Dr. Papapetropoulos served as Chief Development Officer and Senior Vice President, Head of Development at Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) from November 2019 to September 2020 Chief Executive Officer at SwanBio Therapeutics, Inc. from April 2019 to September 2019 and Head of Research & Development and Chief Medical Officer at Cavion, Inc. (acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ)) from June 2017 to April 2019. Before Cavion, Dr. Papapetropoulos held management roles at a number of companies, including Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) from February 2015 to June 2017 Pfizer Inc. (NYSE: PFE) from March 2012 to February 2015 Allergan plc (NYSE: AGN) from May 2010 to March 2012 and Biogen Inc. (NASDAQ: BIIB) from April 2008 to May 2010. Dr. Papapetropoulos was a research professor and subsequently a volunteer professor of neurology at the University of Miami, Miller School of Medicine from November 2008 until August 2017. Dr. Papapetropoulos received his MD and PhD from University of Patras, School of Health Sciences.- Spyros Papapetropoulos自2020年9月起担任我们的首席医疗官。Papapetropoulos博士目前还担任Adamas Pharmaceuticals, Inc.的董事会成员。Nasdaq:ADMS，麻省总医院神经病学顾问。他是Enephalos Life Sciences LLC（神经科学咨询公司）的Founder兼总裁。在加入Vigil之前，Papapetropoulos博士于2019年11月至2020年9月担任Acadia Pharmaceuticals Inc.（纳斯达克市场代码:ACAD）的首席开发官兼高级副总裁，SwanBio Therapeutics的首席执行官，Inc.于2019年4月至2019年9月担任Cavion，Inc.（由Jazz Pharmaceuticals plc（纳斯达克代码:JAZZ）收购）的研发主管兼首席医疗官。在加入Cavion之前，Papapetropoulos博士在多家公司担任管理职位，包括梯瓦制药工业有限公司（纽约证券交易所代码:TEVA）（从2015年2月到2017年6月），辉瑞公司（纽约证券交易所代码:PFE）（从2012年3月到2015年2月），Allergan plc（纽约证券交易所代码:AGN）（从2010年5月到2012年3月）和Biogen Inc.（纳斯达克代码:BIIB）（从2008年4月到2010年5月）。2008年11月至2017年8月，Papapetropoulos博士是迈阿密大学米勒医学院的研究教授，随后担任神经病学志愿教授。Papapetropoulos博士获得了Patras大学健康科学学院的医学博士和博士学位。
- Spyros Papapetropoulos has served as our Chief Medical Officer since September 2020. Dr. Papapetropoulos also currently serves as a member of the board of directors of Adamas Pharmaceuticals, Inc. NASDAQ: ADMS and as a consultant in neurology at Massachusetts General Hospital. He is the founder and President of Encephalos Life Sciences LLC, a neurosciences consulting company. Prior to joining Vigil, Dr. Papapetropoulos served as Chief Development Officer and Senior Vice President, Head of Development at Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) from November 2019 to September 2020 Chief Executive Officer at SwanBio Therapeutics, Inc. from April 2019 to September 2019 and Head of Research & Development and Chief Medical Officer at Cavion, Inc. (acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ)) from June 2017 to April 2019. Before Cavion, Dr. Papapetropoulos held management roles at a number of companies, including Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) from February 2015 to June 2017 Pfizer Inc. (NYSE: PFE) from March 2012 to February 2015 Allergan plc (NYSE: AGN) from May 2010 to March 2012 and Biogen Inc. (NASDAQ: BIIB) from April 2008 to May 2010. Dr. Papapetropoulos was a research professor and subsequently a volunteer professor of neurology at the University of Miami, Miller School of Medicine from November 2008 until August 2017. Dr. Papapetropoulos received his MD and PhD from University of Patras, School of Health Sciences.
- Tim Cunningham
根据公司与Danforth Advisors LLC签订的咨询协议，Tim Cunningham自2023年7月1日起担任Bionomics Limited首席财务官。自2020年9月以来，他一直担任Danforth公司的首席财务官顾问，该公司是一家专注于生命科学公司的战略财务和运营公司，为上市和私营制药和生物技术公司提供首席财务官咨询服务。在加入丹佛斯公司之前，坎宁安曾在Organogenesis公司（纳斯达克股票代码：ORGO）担任首席财务官，在那里他将公司上市，并通过股权和债务融资筹集了超过2.5亿美元，以促进公司的发展。在他的职业生涯中，他曾在多家不同的上市公司和私营公司担任领导职务，他的职业生涯始于纽约的毕马威，之后是普华永道波士顿。坎宁安拥有波士顿大学的MBA学位、波士顿学院的会计学学士学位，并且是佛罗里达州的注册会计师。
Tim Cunningham,has served as Bionomics Limited Chief Financial Officer since July 1, 2023 through a consulting agreement entered into between the Company and Danforth Advisors LLC, or Danforth. He has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company's growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida.- 根据公司与Danforth Advisors LLC签订的咨询协议，Tim Cunningham自2023年7月1日起担任Bionomics Limited首席财务官。自2020年9月以来，他一直担任Danforth公司的首席财务官顾问，该公司是一家专注于生命科学公司的战略财务和运营公司，为上市和私营制药和生物技术公司提供首席财务官咨询服务。在加入丹佛斯公司之前，坎宁安曾在Organogenesis公司（纳斯达克股票代码：ORGO）担任首席财务官，在那里他将公司上市，并通过股权和债务融资筹集了超过2.5亿美元，以促进公司的发展。在他的职业生涯中，他曾在多家不同的上市公司和私营公司担任领导职务，他的职业生涯始于纽约的毕马威，之后是普华永道波士顿。坎宁安拥有波士顿大学的MBA学位、波士顿学院的会计学学士学位，并且是佛罗里达州的注册会计师。
- Tim Cunningham,has served as Bionomics Limited Chief Financial Officer since July 1, 2023 through a consulting agreement entered into between the Company and Danforth Advisors LLC, or Danforth. He has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company's growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida.